3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
12
Prostatic Neoplasms
4
Neoplasms
4
Kidney Neoplasms
3
Carcinoma, Hepatocellular
3
Carcinoma
3
Pain
2
Clear-cell metastatic renal cell carcinoma
2
Carcinoma, Medullary
2
von Hippel-Lindau Disease
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Thyroid cancer, follicular
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Refractory Differentiated Thyroid Gland Carcinoma
1
Non functioning pancreatic endocrine tumor
1
Neuroendocrine Tumors
1
Lymphatic Metastasis
1
Liver Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenoma, Islet Cell
1
Adenocarcinoma, Follicular
1
Interventions
palbociclib
1
lenvatinib
1
cabozantinib
1
belzutifan
1
Nivolumab
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
von Hippel-Lindau Disease
×
cabozantinib
×
Clear all
NCT07405164
2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3
Recruiting
450 enrolled